DIRS.INFO The most relevant business & tech news

☆ Johnson & Johnson forecasts as much as 6% sales growth in 2024
▼ + stars: | 2023-12-05 | by ( ) www.reuters.com time to read: +2 min

Dec 5 (Reuters) - Johnson & Johnson (JNJ.N) on Tuesday forecast revenue growth of 5-6% for the next year, as it banks on strong demand for cancer treatments Darzalex and Carvykti and resilient sales of blockbuster drug Stelara. The company has narrowed its focus on its drugs and medical devices business since it hived off its consumer health unit earlier this year. Sales of blockbuster psoriasis treatment Stelara in Europe are expected to come under pressure as early as next year as a key patent on the drug expires. Sales of the drug largely come from its use as a treatment for inflammatory bowel diseases (IBD), Wolk said. J&J's 2024 revenue growth forecast excludes sales of its COVID vaccine.

Persons: Johnson, Joseph Wolk, Wolk, J, Bhanvi, Patrick Wingrove, Anil D'Silva Organizations: Johnson, Thomson Locations: Europe, United States, Bengaluru, New York

☆ Sanofi CEO under pressure to woo investors after spending shock
▼ + stars: | 2023-12-05 | by ( Ludwig Burger | ) www.reuters.com time to read: +5 min

[1/2] Paul Hudson, chief executive officer of Sanofi, speaks during the annual results news conference at the company's headquarters in Paris, France, February 4, 2022. The market's shock reaction, compounded by a lack of details of the spending push, overshadowed Sanofi's plan to list its consumer unit, in line with an industry trend. David Song, a portfolio manager and investment partner at Tema ETF, said: "The narrative of Sanofi has been a margin expansion, earnings-driven story for a lot of investors." "Shouldn't investors give credit to managements who care about long-term shareholder value creation?," said Song. ($1 = 0.9206 euros)Reporting by Ludwig Burger; Editing by Josephine Mason and Emelia Sithole-MatariseOur Standards: The Thomson Reuters Trust Principles.

Persons: Paul Hudson, Sanofi, Benoit Tessier, Hudson, Dan Lyons, Janus Henderson, Markus Manns, David Song, Fabian Wenner, Julius Baer, Union's Manns, Janus Henderson's Lyons, Johnson, Song, Ludwig Burger, Josephine Mason, Emelia Organizations: REUTERS, Reuters, Janus Henderson Investors, Germany's Union Investment, Tema, Thomson Locations: Paris, France, British, Hudson, Denver, Swiss, Tema

☆ Friday's analyst calls: Big drug stock upgrade, Alibaba downgrade, a new AI play
▼ + stars: | 2023-12-01 | by ( Sarah Min | ) www.cnbc.com time to read: +7 min

The analyst lowered her price target to $99 from $106 per share. The new price target implies just a 5% gain from Thursday's close. The analyst's $115 price target, hiked from $70 previously, implies 43% upside from where the stock closed Thursday, at $80.36. ET: Morgan Stanley downgrades Alibaba Morgan Stanley cut Alibaba to equal-weight from overweight and lowered the firm's price target to $90 from $110. The analyst's $190 price target implies shares can rise just 2.6% from where they closed Thursday.

Persons: JPMorgan downgrades, Jessica Fye, Fye, Sarah Min, Wells Fargo, Andrew Nowinski, GenAI, Nowinski, FactSet, — Sarah Min, Morgan Stanley downgrades Alibaba Morgan Stanley, Alibaba, Morgan Stanley, PDD, John Melloy, Jason Bazinet, Bazinet, Johnson, Danielle Antalffy, Antalffy, Robert Ohmes, — John Melloy Organizations: CNBC, Spotify, JPMorgan, Investors, U.S, PDD Holdings, Citi, UBS, Johnson, Pharma, Bank of America, of America, Costco Locations: BioNTech, Thursday's, Wells Fargo, China, Darzalex, DARZALEX

☆ Focus: Drugmakers go under the skin, skirting early US Medicare price negotiations
▼ + stars: | 2023-07-28 | by ( Michael Erman | ) www.reuters.com time to read: +5 min

Each year, Medicare will add more drugs to the list, the names of which have not yet been disclosed. Faspro, launched in 2020, already accounts for more than 80% of Darzalex revenue, which is due to rise to $9.5 billion this year. Merck previously told Reuters it expects this version of Keytruda could replace the more time consuming infusion for most patients. Keytruda revenue is expected to top $24 billion this year and could exceed $30 billion as soon as 2026, according to analyst estimates. The company has said its expects revenue from subcutaneous drugs containing hyaluronidase to drive its growth going forward.

Persons: Srdjan, Johnson, drugmakers, Bristol Myers, Roche, Biden’s, Michael DiFiore, DiFiore, Joseph Wolk, Faspro, Halozyme, Helen Torley, hyaluronidase, Michael Erman, Patrick Wingrove, Caroline Humer, Bill Berkrot Organizations: U.S, REUTERS, Wall Street, Merck & Co, Halozyme Therapeutics, Reuters, Bristol, Bristol Myers Squibb, Medicare, U.S . Centers, Medicaid Services, J, Reuters Graphics Merck, Merck, Thomson Locations: Ljubljana, Darzalex, Diego

☆ J&J-spinoff Kenvue forecasts upbeat annual profit on strong self-care demand
▼ + stars: | 2023-07-20 | by ( ) www.reuters.com time to read: +2 min

Companies Kenvue Inc FollowNeutrogena Corporation FollowHaleon Plc Follow Show more companiesJuly 20 (Reuters) - Kenvue (KVUE.N), the former consumer health unit of Johnson & Johnson (JNJ.N), forecast full-year profit above Wall Street estimates on Thursday, betting on resilient demand for its skincare and self-care products such as Neutrogena and Tylenol. Kenvue, in its first results after being spun off from Johnson & Johnson in May, forecast full-year adjusted profit per share between $1.26 and $1.31. However, adjusted gross profit margin came in at 57.5%, compared to 59.3% a year earlier, dragged by a strong dollar and higher costs. Meanwhile, J&J raised its 2023 profit forecast on Thursday, banking on the strength in its medical devices business and demand for its cancer drugs such as Darzalex. Net sales rose 5.4% to $4.01 billion while adjusted profit per share came in at 32 cents.

Persons: Johnson, Haleon, J, Ananya Mariam Rajesh, Raghav, Devika Syamnath Organizations: Johnson, Wall, Thomson Locations: Bengaluru

☆ J&J expects cancer drugs, medical devices to drive growth in 2023
▼ + stars: | 2023-07-20 | by ( ) www.reuters.com time to read: +2 min

Shares of J&J, which recently spun off its consumer health unit to focus on drugs and medical devices, rose over 1% in premarket trading. The company expects sales at its pharmaceutical unit to grow more in the second half of 2023, compared with the first half. Quarterly sales of its multiple myeloma drug, Darzalex, were $2.43 billion, in line with Wall Street estimates, according to Refinitiv. Second-quarter sales for its medical device unit were $7.79 billion, topping estimates of $7.55 billion. J&J said it now expects adjusted 2023 profit of $10.70 to $10.80 per share, above estimates of $10.65 per share and its prior forecast of $10.60 to $10.70 per share.

Persons: Johnson, Stelara, J, J's, Bhanvi, Anil D'Silva Organizations: Johnson, Wall, Thomson Locations: Kenvue, Bengaluru

☆ 3 health-care stocks are in the headlines. How the news impacts our investments
▼ + stars: | 2023-07-13 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

In April, alongside its first-quarter results, J & J raised its full-year sales guidance by about $1 billion and its earnings-per-share outlook by 15 cents. Clearing this overhang would help reduce the discount at which J & J shares to pharmaceutical peers, the firm said. The Club's take: JPMorgan's thinking on J & J aligns quite closely with our own. The dark cloud of talc lawsuits continues to keep a lid on J & J's stock price. Joaquin Duato, chief executive officer of Johnson & Johnson, at the company's headquarters in New Brunswick, New Jersey, U.S., on Thursday, April 21, 2022.

Persons: Johnson, Eli Lilly, J, Wells, Wells Fargo, Eli Lilly's, —, Eisai, Biogen, Bloomberg, we've, Jim Cramer's, Jim Cramer, Jim, Joaquin Duato, Amir Hamia Organizations: Johnson, JPMorgan, pharma, U.S ., Humana, UnitedHealth, Bloomberg, U.S, Mayo Clinic, Club, GE Healthcare, CNBC, Getty, & $ Locations: U.S, California, Wells Fargo, Rochester , Minnesota, New Brunswick , New Jersey

Companies Johnson & Johnson FollowApril 18 (Reuters) - Johnson & Johnson (JNJ.N) on Tuesday cautioned investors over the lingering impact of inflation-driven costs this year as the healthcare conglomerate issued a conservative full-year profit forecast, and its shares fell more than 2%. J&J also said it expected a steep decline in sales of its blockbuster Crohn's disease drug Stelara once it loses U.S. patent protection in late 2023. J&J, the first large drugmaker and medical device manufacturer to report earnings, raised the midpoint of its full-year profit forecast by 10 cents despite beating first-quarter estimates by 18 cents. A recovery in medical procedures after being weighed down by hospital staffing shortages helped the medical device unit post sales of $7.48 billion, topping analysts' estimates of $7.31 billion. Consumer health sales rose 7.4% to $3.85 billion, surpassing estimates of $3.62 billion, powered by price hikes to offset the impact from inflation.

☆ Johnson & Johnson (JNJ) earnings Q1 2023
▼ + stars: | 2023-04-18 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +5 min

Johnson & Johnson shares fell Tuesday after the company reported adjusted earnings and revenue that topped Wall Street's expectations, but lowered its sales guidance for its pharmaceutical business. J&J is now forecasting 2023 sales of $97.9 billion to $98.9 billion, about $1 billion higher than the guidance provided in January. Lawsuits allege the company's talc products were contaminated with the carcinogen asbestos, which caused ovarian cancer in thousands of individuals. Some suits link several deaths to J&J's talc products. Read the full J&J earnings report.

☆ Earnings playbook: Netflix and Goldman Sachs headline a big week of reports
▼ + stars: | 2023-04-16 | by ( Fred Imbert | ) www.cnbc.com time to read: +14 min

Tuesday Johnson & Johnson is set to report earnings before the open, followed by a call with management at 8:30 a.m. Goldman Sachs is set to report earnings before the open, followed by a call at 9:30 a.m. What history shows: Bespoke data shows Goldman tops earnings expectations 86% of the time. Netflix is set to report earnings after the bell, followed by a call with management at 6 p.m. Friday Procter & Gamble is set to report earnings before the open, with a conference call also slated for 8:30 a.m.

But COVID-19 vaccine sales exceeded diminished expectations and demand for cancer drug Darzalex helped drive the fourth-quarter profit beat. The company reported $689 million in quarterly COVID-19 vaccine sales from outside the United States. J&J said it expects U.S. sales of Stelara to be flat to lower in 2023 due to competition from less expensive biosimilars in certain regions. It forecast adjusted 2023 earnings of $10.45 to $10.65 per share, above analysts' estimates of $10.35. Excluding items, J&J earned $2.35 per share for the quarter, topping analysts' estimates by 12 cents, according to IBES data from Refinitiv.

Organizations: & $

☆ J&J forecasts 2023 profit above expectations on pharma strength
▼ + stars: | 2023-01-24 | by ( ) www.reuters.com time to read: +2 min

Shares of the drugmaker, however, fell 1% to $166.12 in premarket trading as fourth-quarter sales missed analysts' estimates due to lower demand for its medical devices. J&J expects to earn between $10.45 and $10.65 per share on an adjusted basis for 2023, above analysts' estimates of $10.35 per share profit at the midpoint. The higher 2023 profit forecast also reflects better-than-expected cost controls by J&J, Edward Jones analyst John Boylan said. Darzalex sales were $2.08 billion, while analysts were expecting $2.02 billion, according to Refinitiv. Excluding items, J&J earned $2.35 per share, above analysts' average estimates of $2.23 per share, according to IBES data from Refinitiv.

Organizations: & $

☆ Johnson & Johnson deserves more credit for another healthy quarter and strong guidance
▼ + stars: | 2023-01-24 | by ( Jeff Marks | ) www.cnbc.com time to read: +6 min

Johnson & Johnson (JNJ) posted another solid quarter of healthy growth — and another productive year of free-cash-flow generation — despite a slight miss on sales. On an adjusted operational basis, which excludes the impact of acquisitions and divestitures and currency, sales rose 0.8%. But the new year has been tough on pharmaceutical stocks and almost all of health care, including JNJ stock, which is down 6% year to date. Johnson & Johnson forecasts adjusted EPS on an operational basis to grow 2.5% to 4.5%, which at a midpoint of $10.50 compares favorably to the consensus of $10.33. Its addition to the MedTech division is expected to help accelerate sales growth this year.

☆ J&J beats estimates on demand for cancer drug
▼ + stars: | 2022-10-18 | by ( Nancy Lapid | ) www.reuters.com time to read: +2 min

Oct 18 (Reuters) - Johnson & Johnson (JNJ.N) on Tuesday beat Wall Street estimates for quarterly revenue and profit on strong demand for its cancer drug Darzalex and Crohn's disease drug Stelara while projecting an easing of the hit from surging inflation. The company, which also sells medical devices and consumer health products such as Band Aids and painkiller Tylenol, tightened its full-year adjusted profit forecast range. J&J is the first drugmaker and medical devices firm to report third-quarter earnings and its shares rose 2.1% to $170.02 in premarket trading. The medical devices unit reported a 2.1% rise in sales to $6.78 billion on demand for contact lenses and wound-closure products. Total sales for the third-quarter rose 1.9% to $23.79 billion, topping estimates of $23.34 billion, according to Refinitiv IBES data.

Organizations: & $

☆ J&J stock dip after earnings beat reflects 2022 outperformance rather than the results
▼ + stars: | 2022-10-18 | by ( Zev Fima | ) www.cnbc.com time to read: +11 min

On an adjusted operational basis, which excludes the impact of acquisitions and divestitures and currency, sales rose 8.2%. Management said on the call they continue to see this business on track for its 11th consecutive year of above-market adjusted operational sales growth in 2022. Driving the results were increased sales of Stelara on the back of market growth and market share gains in Crohn's Disease and Ulcerative Colitis. Women's Health sales increased 7.9% on an operational basis to $225 million versus the $222 million expected. On a reported basis, management tightened their EPS guidance range to $10.02 to $10.07 from $10 to $10.10 previously.

Johnson & Johnson (JNJ.N) rose 1.5% in premarket trading after the healthcare conglomerate beat Wall Street expectations for third-quarter sales, helped by strong demand for its cancer drug Darzalex and Crohn's disease drug Stelara. read moreGoldman Sachs Group Inc (GS.N) gained 0.9%, while Netflix (NFLX.O) added 1.6% ahead of earnings later in the day. read moreThe reversal of parts of a controversial UK fiscal plan that had roiled bond markets also aided sentiment. read more"Initial Q3 company reports have been positive, and you've had some stabilization in the United Kingdom with its government. ET, Dow e-minis were up 340 points, or 1.12%, S&P 500 e-minis were up 50.25 points, or 1.36%, and Nasdaq 100 e-minis were up 179.75 points, or 1.62%.

☆ What Cramer is watching Tuesday — J&J beat, Salesforce gets an activist, stocks surge
▼ + stars: | 2022-10-18 | by ( Jim Cramer | ) www.cnbc.com time to read: +5 min

What I am looking at Tuesday, Oct. 18, 2022 Club holding Johnson & Johnson (JNJ) reports an impressive quarter. Activist investor Starboard takes a major stake in Club holding Salesforce (CRM), sees significant opportunity. Club holding Microsoft (MSFT) cuts people, continues to invest, but calls for slowest quarterly revenue growth in more than five years. Barclays cuts price target on Charles Schwab (SCHW) to $73 per share from $81. Barclays cuts price target on Unity Software (U) to $33 per share from $49.

Search resuls for: "Darzalex"

17 mentions found